摘要
糖尿病是一类以高血糖为主要临床表现的代谢性疾病,往往同时伴发高血脂、高血压等疾病,临床常需要给予包括降糖、降压、调脂、抗凝、减重等在内的综合管理手段。而随着综合管理措施的增加,联合用药的种类越多,药物间相互作用的发生风险越高,而临床上90%以上的代谢性药物相互作用都与CYP450酶和P糖蛋白转运途径相关。二肽基肽酶-4(dipeptidyl peptidase-4 inhibitors,DPP-4)抑制剂作为新型降糖药物,在临床中被广泛应用。本文将重点阐述CYP450酶和P糖蛋白对该类药物联用其他药物后在降糖疗效方面的影响,以期引起更多临床医生的重视,更好地帮助临床使用这一类药物。
Diabetes was a group of metabolic disorders characterized byhyperglycemia. Meanwhile, diabetes patients often comorbid cardiovascular diseases, such as hypertension, hyperlipidemia, therefore required comprehensive management such as lowering blood glucose, blood pressure and blood lipid and weight reduction. 90% drug interactions were correlated with CYP450 enzyme and P-glycoprotein transportation pathway. Dipeptidyl peptidase-4 inhibitors (DPP-4i) were widely used in clinics as novel anti-hyperglycemic agent. This review would focus on effect of CYP450 and P-glycoprotein on drug interaction during combinational treatment of DPP-4i and others drugs, aimed to draw more attention of clinicians and better clinical applications of DPP-4i.
作者
母义明
MU Yi-ming(Department of Endocrinology, General Hospital of Chinese PLA, Beijing 100853, China)
出处
《药品评价》
CAS
2019年第7期13-16,共4页
Drug Evaluation
关键词
联合用药
糖尿病
二肽基肽酶-4
药物相互作用
Combination Therapy
Diabetes
Dipeptidyl Peptidase-4 Inhibitor (DPP-4i)
Drug-drug Interactions
